Biogen Overview

  • Founded
  • 1978

Founded
  • Status
  • Public

  • Employees
  • 9,610

Employees
  • Stock Symbol
  • BIIB

Stock Symbol
  • Investments
  • 63

  • Share Price
  • $210.63

  • (As of Friday Closing)

Biogen General Information

Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Contact Information

Website
www.biogen.com
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$210.63 $203.94 $187.16 - $372.12 $30.8B 146M 1.13M $9.79

Biogen Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 34,814,864 40,358,499 41,919,748 55,465,018
Revenue 10,819,500 10,981,700 13,444,600 14,377,900
EBITDA 2,397,900 2,475,500 5,685,200 7,658,000
Net Income 1,449,700 1,556,100 4,000,600 5,888,500
Total Assets 23,614,400 23,877,300 24,618,900 27,234,300
Total Debt 7,587,500 7,603,500 7,828,200 6,367,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Biotechnology
Cambridge, MA
9,610 As of 2021
000.00
000 0000-00-00
0&0

000000

modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
000000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000

000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biogen Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ironwood Pharmaceuticals Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000&0
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 0000000000 Corporate Backed or Acquired Allschwil, Switzerland 0000 00.000 00000000 00.000
You’re viewing 5 of 22 competitors. Get the full list »

Biogen Patents

Biogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210102939-A1 Assay for jc virus antibodies Pending 07-Oct-2019 000000000000
CA-3139545-A1 Convergent liquid phase syntheses of oligonucleotides Pending 08-May-2019 00000000
AU-2020271856-A1 Process for preparing alpha-carboxamide pyrrolidine derivatives Pending 10-Apr-2019 0000000000
CA-3136536-A1 Process for preparing alpha-carboxamide pyrrolidine derivatives Pending 10-Apr-2019 0000000000
CA-3136426-A1 Processes for preparing alpha-carboxamide pyrrolidine derivatives Pending 10-Apr-2019 C07C233/51
To view Biogen’s complete patent history, request access »

Biogen Executive Team (87)

Name Title Board Seat Contact Info
Michel Vounatsos Chief Executive Officer & Board Member
Michael Mcdonnell Chief Financial Officer & Executive Vice President
Robin Kramer Head of Global Business Services and Treasury, Chief Accounting Officer & Senior Vice President
Idan Aharon Director, Early & External Product Commercialization
Aldemar Degroot Ph.D Director, External Innovation Lead EU, Canada and Partner Markets
You’re viewing 5 of 87 executive team members. Get the full list »

Biogen Board Members (22)

Name Representing Role Since
Alexander Denner Ph.D Self Board Member 000 0000
Brian Posner Self Board Member & Chairman of the Compensation and Management Development Committee 000 0000
Caroline Dorsa Biogen Board Member & Chairwoman of the Audit Committee 000 0000
Eric Rowinsky MD Self Board Member 000 0000
George Scangos Ph.D Self Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 22 board members. Get the full list »

Biogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Investments & Acquisitions (63)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 11-Jan-2021 00000 0000 00000 Drug Delivery
0000 00000000 31-Dec-2020 0000 00000 Biotechnology 000000 00
000000 000000 06-Oct-2020 00000 0000 0000 Discovery Tools (Healthcare)
000000 000000 22-Sep-2020 0000 00000 Biotechnology 000000 00
Autobahn (Drug Discovery) 09-Jun-2020 Early Stage VC 000.00 Drug Discovery
You’re viewing 5 of 63 investments and acquisitions. Get the full list »

Biogen Subsidiaries (2)

Company Name Industry Location Founded
AliveGen USA Biotechnology Thousand Oaks, CA 2014
0000000 Biotechnology NC 0000
To view Biogen’s complete subsidiaries history, request access »

Biogen Exits (30)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000 01-Nov-2018 000000000 00000000 00000 Completed
  • 000000
00000 00000000000 30-Mar-2017 00000 00000 00 0000 Completed
  • 8 buyers
00000000 000000000 18-Feb-2016 00000 00000 00 0000 Completed
  • 7 buyers
00000 000000000000 06-Jan-2016 00000 00000 00 000.00 Completed
  • 3 buyers
Solid GT 03-Nov-2015 Early Stage VC 000.00 Completed
  • 6 buyers
You’re viewing 5 of 30 exits. Get the full list »